{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:50:39Z","timestamp":1792115439425,"version":"4.4.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2018.6007","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T16:31:28Z","timestamp":1547829088000},"page":"e186007","source":"Crossref","is-referenced-by-count":176,"title":["Association of Pharmaceutical Industry Marketing of Opioid Products With Mortality From Opioid-Related Overdoses"],"prefix":"10.1001","volume":"2","author":[{"given":"Scott E.","family":"Hadland","sequence":"first","affiliation":[{"name":"Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts"},{"name":"Department of Pediatrics, Boston Medical Center, Boston, Massachusetts"},{"name":"Grayken Center for Addiction, Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadne","family":"Rivera-Aguirre","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, School of Medicine, University of California at Davis, Sacramento"},{"name":"Department of Population Health, New York University School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon D. L.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Cerd\u00e1","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, School of Medicine, University of California at Davis, Sacramento"},{"name":"Department of Population Health, New York University School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"issue":"12","key":"zoi180253r1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.15585\/mmwr.mm6712a1","article-title":"Overdose deaths involving opioids, cocaine, and psychostimulants\u2014United States, 2015-2016.","volume":"67","author":"Seth","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"zoi180253r2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2105\/AJPH.2017.304265","article-title":"Quantifying the epidemic of prescription opioid overdose deaths.","volume":"108","author":"Seth","year":"2018","journal-title":"Am J Public Health"},{"key":"zoi180253r3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.addbeh.2017.05.030","article-title":"Increased use of heroin as an initiating opioid of abuse.","volume":"74","author":"Cicero","year":"2017","journal-title":"Addict Behav"},{"issue":"26","key":"zoi180253r5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital signs: changes in opioid prescribing in the United States, 2006-2015.","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"zoi180253r7","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016.","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"zoi180253r9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","article-title":"Pharmaceutical industry\u2013sponsored meals and physician prescribing patterns for Medicare beneficiaries.","volume":"176","author":"DeJong","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi180253r10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamainternmed.2016.1709","article-title":"Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts.","volume":"176","author":"Yeh","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi180253r11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/jamainternmed.2018.1999","article-title":"Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing.","volume":"178","author":"Hadland","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"9","key":"zoi180253r12","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2105\/AJPH.2017.303982","article-title":"Industry payments to physicians for opioid products, 2013-2015.","volume":"107","author":"Hadland","year":"2017","journal-title":"Am J Public Health"},{"issue":"6","key":"zoi180253r13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamainternmed.2015.0914","article-title":"Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.","volume":"175","author":"Larochelle","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi180253r14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","article-title":"The promotion and marketing of oxycontin: commercial triumph, public health tragedy.","volume":"99","author":"Van Zee","year":"2009","journal-title":"Am J Public Health"},{"issue":"12","key":"zoi180253r15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1503\/cmaj.090784","article-title":"Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.","volume":"181","author":"Dhalla","year":"2009","journal-title":"CMAJ"},{"issue":"6","key":"zoi180253r16","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/EDE.0b013e3181577654","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"18","author":"von Elm","year":"2007","journal-title":"Epidemiology"},{"issue":"6","key":"zoi180253r25","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMp1803661","article-title":"Opioid prescribing limits for acute pain\u2014striking the right balance.","volume":"379","author":"Lowenstein","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi180253r27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1037\/a0031034","article-title":"Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros.","volume":"18","author":"Valeri","year":"2013","journal-title":"Psychol Methods"},{"issue":"50-51","key":"zoi180253r30","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths\u2014United States, 2010-2015.","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi180253r31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.drugalcdep.2017.05.047","article-title":"Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances.","volume":"178","author":"Kandel","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"zoi180253r32","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11606-009-0989-6","article-title":"Prescribers and pharmaceutical representatives: why are we still meeting?","volume":"24","author":"Fischer","year":"2009","journal-title":"J Gen Intern Med"},{"issue":"17","key":"zoi180253r33","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1001\/jama.2017.4039","article-title":"Association between academic medical center pharmaceutical detailing policies and physician prescribing.","volume":"317","author":"Larkin","year":"2017","journal-title":"JAMA"},{"issue":"17","key":"zoi180253r35","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jama.2017.3091","article-title":"Types and distribution of payments from industry to physicians in 2015.","volume":"317","author":"Tringale","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"zoi180253r36","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/00325481.2017.1268902","article-title":"Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.","volume":"129","author":"Webster","year":"2017","journal-title":"Postgrad Med"},{"issue":"1","key":"zoi180253r38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08897077.2016.1261070","article-title":"Turning the tide or riptide? the changing opioid epidemic.","volume":"38","author":"Kertesz","year":"2017","journal-title":"Subst Abus"},{"key":"zoi180253r39","doi-asserted-by":"publisher","first-page":"k2480","DOI":"10.1136\/bmj.k2480","article-title":"Tighter prescribing regulations drive illicit opioid sales.","volume":"361","author":"Hadland","year":"2018","journal-title":"BMJ"},{"key":"zoi180253r6","volume-title":"Wide-Ranging Online Data for Epidemiologic Research (WONDER)","author":"Centers for Disease Control and Prevention","year":"2018"},{"key":"zoi180253r26","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511814365","volume-title":"Regression Analysis of Count Data","author":"Cameron","year":"1998"},{"key":"zoi180253r28","first-page":"525","volume-title":"Econometric Analysis of Cross Section and Panel Data","author":"Wooldridge","year":"2002"},{"key":"zoi180253r29","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"zoi180253r4","unstructured":"International Narcotics Control Board. Narcotic drugs. https:\/\/www.incb.org\/documents\/Narcotic-Drugs\/Technical-Publications\/2016\/Narcotic_Drugs_Publication_2016.pdf. Published 2016. Accessed October 6, 2017."},{"key":"zoi180253r8","unstructured":"HughesE. The pain hustlers. New York Times Magazine. May 2, 2018. https:\/\/www.nytimes.com\/interactive\/2018\/05\/02\/magazine\/money-issue-insys-opioids-kickbacks.html. Accessed May 15, 2018."},{"key":"zoi180253r17","unstructured":"Centers for Medicare & Medicaid Services. Complete 2014 program year Open Payments dataset. https:\/\/www.cms.gov\/openpayments\/explore-the-data\/dataset-downloads.html. Published 2018. Accessed February 12, 2018."},{"key":"zoi180253r18","unstructured":"US Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM518672.pdf. Published August 31, 2016. Accessed October 11, 2017."},{"key":"zoi180253r19","unstructured":"Centers for Disease Control and Prevention. US opioid prescribing rate maps. https:\/\/www.cdc.gov\/drugoverdose\/maps\/rxrate-maps.html. Accessed January 8, 2018."},{"key":"zoi180253r20","unstructured":"Social Explorer. US Census Bureau American Community Survey 2013. http:\/\/www.socialexplorer.com\/pub\/reportdata\/HtmlResults.aspx?reportid=R11491080. Accessed January 15, 2018."},{"key":"zoi180253r21","unstructured":"Social Explorer. US Census Bureau American Community Survey 2014. http:\/\/www.socialexplorer.com\/pub\/reportdata\/HtmlResults.aspx?reportid=R11491200. Accessed January 15, 2018."},{"key":"zoi180253r22","unstructured":"Social Explorer. US Census Bureau American Community Survey 2015. http:\/\/www.socialexplorer.com\/pub\/reportdata\/HtmlResults.aspx?reportid=R11531828. Accessed January 15, 2018."},{"key":"zoi180253r23","unstructured":"Social Explorer. US Census Bureau American Community Survey 2016. http:\/\/www.socialexplorer.com\/pub\/reportdata\/HtmlResults.aspx?reportid=R11619767. Accessed January 15, 2018."},{"key":"zoi180253r24","unstructured":"US Department of Agriculture. Rural-urban continuum codes. https:\/\/www.ers.usda.gov\/data-products\/rural-urban-continuum-codes\/. Published May 10, 2013. Accessed January 15, 2018."},{"key":"zoi180253r34","unstructured":"FrellickM. New Jersey rule limits physician-pharma interactions. Medscape. https:\/\/www.medscape.com\/viewarticle\/891304. Published January 12, 2018. Accessed February 11, 2018."},{"key":"zoi180253r37","unstructured":"WhalenJ. Purdue Pharma to stop promoting OxyContin to US doctors. Wall Street Journal. February 2, 2018. https:\/\/www.wsj.com\/articles\/purdue-pharma-to-stop-promoting-oxycontin-to-u-s-doctors-1518307565. Accessed November 19, 2018."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/1\/e186007\/17392853\/hadland_2019_oi_180253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T15:00:47Z","timestamp":1553266847000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2018.6007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.6007","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]}}}